Acrus Biomed is to start a new production of biomedical cell products to restore skin and soft tissues by June, 2021. Investor is going to spend 343 million Rubles on the project, informed Vladimir Efimov, Deputy Mayor of Moscow for economic policy and property and land relations.  

A new manufacturing with a total area of more than 800 м² will be located on the territory of special economic zone Technopolis Moscow in Pechatniki.

“The company will create two new unique biomedical cell products. Biologic drugs will be supplied to healthcare facilities, burn centers and disaster medicine centers of the Central Federal District. Project investments will amount to 343 million Rubles leading to no less than 50 new jobs”, specified Vice-Mayor.

The development of biomedical cell products was supported by a special project of the Ministry of Science and Higher Education of the Russian Federation within the Federal target program “Research and Development”.

“Now the company Acrus Biomed is leading clinical trial and will launch the production in one year. SEZ tenant is to produce up to 72 thousand units per year”, said Alexander Prokhorov, Head of the Department of investment and industrial policy of Moscow.

Resident status and the location in Technopolis provides the company with up to 47% savings on taxes and other obligatory payments also ensuring access to central traffic routes and proximity to future customers – healthcare centers of the capital city.

“There will be a biobank of the company on the territory of Technopolis available for other producers of biomedical cell products“, added Gennady Degtev, CEO of SEZ Technopolis Moscow.

The company involves the leading scientific agencies of the capital city into the production of biomedical cell products on the territory of SEZ, shared Igor Abashin, CEO of Acrus Biomed.

“The company has invested in different scientific and research projects for several years. For example Acrus Biomed has invested 125 million Rubles in the project “Technology development for the production, storage and application of biomedical cell products for wound healing” executed together with Koltzov Institute of Developmental Biology of RAS. Other parts of the project are Moscow State University and Privolzhsky Federal Research Center of Ministry of Health of the Russian Federation. Such cooperation leads to monetization of scientific developments and stronger interaction of science and business”, added Igor Abashin. 

Ваш вопрос